One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients

BACKGROUND: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study was designed to examine the safety and effectiveness of 1-m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circ Cardiovasc Interv
Autors principals: Kandzari, David E., Kirtane, Ajay J., Windecker, Stephan, Latib, Azeem, Kedhi, Elvin, Mehran, Roxana, Price, Matthew J., Abizaid, Alexandre, Simon, Daniel I., Worthley, Stephen G., Zaman, Azfar, Choi, James W., Caputo, Ronald, Kanitkar, Mihir, McLaurin, Brent, Potluri, Srinivasa, Smith, Timothy, Spriggs, Douglas, Tolleson, Thaddeus, Nazif, Tamim, Parke, Maria, Lee, Lilian C., Lung, Te-Hsin, Stone, Gregg W.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665241/
https://ncbi.nlm.nih.gov/pubmed/33167705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars